Mean fasting plasma glucose concentration decreased over the study period with vildagliptin vs placebo by -1.0 mmol/L ( P = .018 ) , and there was a positive correlation between these decrements and liver triglyceride in the vildagliptin group at 3 months ( r = 0.47 ; P = .02 ) and 6 months ( r = 0.44 ; P = .03 ) .